WuXi will build and operate a dedicated facility in Shanghai.
WuXi PharmaTech will conduct stability studies of small molecule NCEs for Bristol-Myers Squibb to support global marketing applications. Under the agreement WuXi will build, equip, and operate a dedicated, fully cGMP-compliant 25,000 square foot analytical testing facility in Shanghai.
It will store and test stability samples and perform other services for BMS at this site. WuXi will also employ a dedicated staff for stability testing, sample management, analytical testing, pharmaceutical science, quality assurance, metrology, and other services including stability data reporting in support of all global dossier submissions by Bristol-Myers Squibb.
“WuXi PharmaTech is an important partner for Bristol-Myers Squibb’s research and development organization,” notes Mark Powell, Ph.D., senior vice president, nonclinical development, Bristol-Myers Squibb. “This agreement will expand the scope of our relationship with WuXi and enhance the presence of Bristol-Myers Squibb in China.”
